INDV Share Price Performance
UK£12.38
2.70 (27.89%)
18.7% overvalued intrinsic discount
UK£10.43
Fair Value
Price UK£12.38
AnalystConsensusTarget UK£10.43
Fair ValueUK£10.43
Share Pricen/a
Indivior PLC Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
INDV Community Narratives
AN
Fair Value UK£10.43 18.7% overvalued intrinsic discount
SUBLOCADE Investments Will Improve Patient And Physician Experience
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
SUBLOCADE Investments Will Improve Patient And Physician Experience
Key Takeaways Commercial investments and label updates for SUBLOCADE are expected to boost revenue growth and enhance patient and physician experience. Strategic reinvestments and U.S. market stabilization could strengthen revenue projections and profit margins for Indivior.Read more
24
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
UK£10.43
18.7% overvalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
-0.92% p.a.
Profit Margin
17.86%
Future PE
8.3x
Price in 2028
UK£12.32
Trending Discussion
Recently Updated Narratives
AN
SUBLOCADE Investments Will Improve Patient And Physician Experience
Fair Value: UK£10.43 18.7% overvalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Indivior PLC Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Jul 31, 2025
- -0.50
- 81.62%
- -5.30%
- -115.4%
About INDV
- Founded
- 2014
- Employees
- 1041
- CEO
- WebsiteView website
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
